EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent

Hannah Painter iD, Sasha E Larsen iD, Brittany D Williams, Hazem F M Abdelaal, Susan L Baldwin, Helen A Fletcher, Andrew Fiore-Gartland iD, Rhea N Coler iD

mSphere · 2025

DOI: 10.1128/msphere.00864-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2025. Verfasst von Hannah Painter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: Tuberculosis, RNA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, MRC and BBSRC, UK Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is unclear whether human progression to active tuberculosis disease (TB) risk signatures are viable endpoint criteria for evaluations of treatments in development. TB is the deadliest infectious disease globally and more efficacious vaccines are needed to reduce this mortality. However, the immune correlates of protection for either preventing infection with Mycobacterium tuberculosis or preventing TB disease have yet to be completely defined, making the advancement of candidate vaccines through the pipeline slow, costly, and fraught with risk. Human-derived correlate of risk (COR) gene signatures, which identify an individual’s risk of progressing to active TB disease, provide an opportunity for evaluating new therapies for TB with clear and defined endpoints. Though prospective clinical trials with longitudinal sampling are prohibitively expensive, the characterization of COR gene signatures is practical with preclinical models. Using a 3Rs (replacement, reduction, and refinement) approach we reanalyzed heterogeneous publicly available transcriptional data sets to determine whether a specific set of COR signatures are viable endpoints in the preclinical pipeline. We selected RISK6, Sweeney3, and BATF2 human-derived blood-based RNA biosignatures because they require relatively few genes and have been carefully evaluated across several clinical cohorts. These data suggest that in certain experimental designs and in several tissue types, human COR signatures correlate with disease progression as measured by the bacterial burden in the preclinical TB model pipeline. We observed the best performance when the model most closely reflected human infection or disease conditions. Human-derived COR signatures offer an opportunity for high-throughput preclinical endpoint criteria of vaccine and drug therapy evaluations. IMPORTANCE Understanding the strengths or limitations of back-translating human-derived correlate of risk (COR) RNA signatures into the preclinical pipeline may help streamline down-selection of therapeutic vaccine and drug candidates and better align preclinical models with proposed clinical trial efficacy endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisRNAHumansMycobacterium tuberculosisTuberculosis VaccinesTranscriptomeDisease Progression

Stichwörter der Autor:innen

RNA risk signaturecorrelate of riskpreclinical drug studiestuberculosistuberculosis vaccines

Substanzen

Tuberculosis VaccinesRNA

Autor:innen und Institutionen

  • Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Biostatistics, Bioinformatics and Epidemiology Program, Fred Hutch Cancer Center, Seattle, Washington, USA.
  • Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Hannah Painter, Sasha E Larsen, Andrew Fiore-Gartland, Rhea N Coler

Förderung

  • NIAID NIH HHS
  • MRC and BBSRC
  • UK Medical Research Council
  • National Institutes of Health

Zitieren

APA

Painter, H., Larsen, S. E., Williams, B. D., Abdelaal, H. F. M., Baldwin, S. L., Fletcher, H. A., Fiore-Gartland, A., & Coler, R. N. (2025). Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent. mSphere. https://doi.org/10.1128/msphere.00864-24

Vancouver

Painter H, Larsen SE, Williams BD, Abdelaal HFM, Baldwin SL, Fletcher HA, et al. Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent. mSphere. 2025. doi:10.1128/msphere.00864-24

BibTeX
@article{Painter2025,
  author = {Painter, Hannah and Larsen, Sasha E and Williams, Brittany D and Abdelaal, Hazem F M and Baldwin, Susan L and Fletcher, Helen A and Fiore-Gartland, Andrew and Coler, Rhea N},
  title = {Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent},
  journal = {mSphere},
  year = {2025},
  doi = {10.1128/msphere.00864-24}
}
Kostenlos starten →